MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE | N215344 | AZURITY PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
AZURITY PHARMACEUTICALS, INC. v. STRIDES PHARMA INC. et al 1 patentANDA 220202polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride | D.N.J. | 2025-10-17 | Active | — |
AZURITY PHARMACEUTICALS, INC. v. LUPIN LIMITED et al 2 patentsANDA 220363polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride | D.N.J. | 2025-07-10 | Active | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$61.65
per ea
Lowest NADAC/Unit
$61.65
per ea
Brand NDCs
1
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 52268055001SUFLAVE POWDER | $61.65 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.